Showing posts with label amyloid plaques. Show all posts
Showing posts with label amyloid plaques. Show all posts

Tuesday, December 4, 2012

Psoriasis drug may halt or reverse Alzheimer's disease



Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition


LA Times

A biological medication already widely used to treat plaquepsoriasis may be able to slow the accumulation of amyloid plaques in the brain that are the hallmark of Alzheimer's disease, a new study has found. The same study found that in older mice with established Alzheimer's, this treatment approach, which suppresses the brain's immune reaction to beta amyloid, brought a marked improvement in cognitive function and may even halt or reverse early signs of Alzheimer's.
The new study was published this week in the journal Nature Medicine.
Conducted by researchers in Switzerland and Germany, the study offers a glimmer of hope in the thus-far discouraging search for a therapy that could halt or reverse the inexorable process of neuronal loss and mental decline that affects some 35-million people worldwide. It also strengthens evidence for the long-suspected role of inflammation in the development of Alzheimer's disease.
The authors of the study suggest that researchers should immediately launch clinical trials of ustekinumab — a biologic drug already approved by the Food & Drug Administration for the treatment of plaque psoriasis (and marketed as Stelara) — on patients with mild cognitive impairment or very early Alzheimer's disease. They called agents that shut down specific immune responses — medications tested in auto-immune disorders such as psoriasis, Crohn's disease and multiple sclerosis — "the ideal candidate for the initiation of clinical trials" for Alzheimer's.
"This kind of research is a step forward in identifying potential human targets for drug action," said Dr. Lon Schneider, director of pharmacological research at USC's Alzheimer's Disease Research Center, who was not involved with the current study.

At the same time, Schneider cautioned against drawing too much hope from the latest research. In animal models of Alzheimer's disease, he said, interventions that seem to work for mice "have not translated to humans," he said. And even when an existing drug appears promising, he added, researchers are far from knowing what dose or form of administration will be safe and effective for humans.
"Using the drug off the shelf may not be either" safe or effective, he warned.
The latest research focuses on the role of the immune system in the degenerative process at the heart of Alzheimer's. Looking at the cerebrospinal fluid of 39 human subjects with established Alzheimer's disease and 20 healthy control subjects, the researchers showed that the accumulation of beta-amyloid in the brain may set off an immune reaction — including the release of two proteins known as interleukin-12 and interleukin-23.
These two chemicals, collectively called IL-12/23, send forth a signaling molecule called P40 that increases inflammation across the brain. Past research suggests that in brains where P40 is in plentiful supply, beta-amyloid particles that are circulating form plaques. Those plaques, in turn, disrupt signaling throughout the brain and appear to  cause the decline in memory and mental function so familiar to the loved ones of those with the devastating disease.
Researchers have sought to suppress IL-12/23 by different means. But among the most successful so far have been the injection of antibodies that shut down P40's signal. When the authors of the study injected P40 antibodies and an inactive control substance into young mice who were genetically programmed to develop Alzheimer's disease, they saw a distinct difference: At about middle age, the mice that got the P40 antibodies had 31% less beta-amyloid plaque in their brains than their peers who got the placebo.
The researchers also sought to test the effect of suppressing P40 in rats with established Alzheimer's disease. They implanted mini-pumps that for 60 days infused P40 antibodies directly into the brains of older rats with full-blown Alzheimer's. Another group of such rats got a placebo infusion. The treated mice performed far better than those who got the placebo in tests of memory and cognitive function. And while the treated mice still had amyloid plaques, there was far less beta-amyloid in their brains available to form new ones.
See recent reports of other drugs that have generated hope for Alzheimer's disease:

Thursday, June 21, 2012

Amyvid in diagnosing Alzheimer's


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire




Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Lilly


INDIANAPOLIS, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly announced that Amyvid is available to imaging centers in markets surrounding 16 manufacturing sites located in Atlanta; Charlotte, N.C.; Chicago; Colton, Calif;Columbus, Ohio; Dallas; Fort Lauderdale, Fla.; Hartford, Conn.; Houston; Jacksonville, Fla.; North Wales, Pa.; Orlando, Fla.; Palo Alto, Calif.; Phoenix; Seattle; and St. Louis.
Because Amyvid loses over half of its radioactivity every two hours, it must be distributed directly to imaging centers from the specialized radiopharmacies where it is produced. Patients should speak to their health care provider to determine if Amyvid is an appropriate option for them and to determine if it is available in their area. 
"In the roughly two months since the approval of Amyvid, we have been working closely with imaging centers to ensure they are prepared to provide Amyvid to their customers," said Daniel Skovronsky, M.D., Ph.D., president and CEO of Avid, and global brand development leader for Amyvid at Lilly. "We are committed to providing Amyvid to physicians, patients and their families in as many areas as possible as quickly as we can."
To coincide with the availability of Amyvid, Lilly is also announcing the launch of their reader training program. An online training program, developed by Lilly and Avid, is now available at AmyvidTraining.com. The companies also collaborated with the American College of Radiology to present a live, in-person training program, which will be launched on June 11, 2012, in Miami. These reader training programs were developed to provide training for radiologists and nuclear medicine physicians who will be responsible for reading Amyvid scans. Amyvid images should be interpreted only by readers who have successfully completed the Amyvid reader training. Errors may occur in the estimation of plaque density during image interpretation.
Amyvid is the first-and-only radioactive diagnostic agent approved by the U.S. Food and Drug Administration for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.(1)
Amyvid works by binding to amyloid plaques, one of the necessary pathological features of Alzheimer's Disease,(2),(3),(4) and is detected using PET scan images of the brain.(1)  A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease.(2),(5) A positive Amyvid scan indicates moderate to frequent amyloid plaques are present; this amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.(1),(4),(6)
It's important to note that Amyvid is an adjunct to other diagnostic evaluations. A positive Amyvid scan does not establish a diagnosis of Alzheimer's Disease or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or monitoring responses to therapies.(1)
About Amyvid
Amyvid is a radioactive diagnostic agent, tagged with a radioisotope called fluorine-18. Once Amyvid is injected into a vein, it travels through the bloodstream and into the brain, binding to amyloid plaques. Amyvid produces a positron signal, which is detected by a PET scanner and used to create a brain image. A radiologist, who should have successfully completed Amyvid reader training, then interprets the image to evaluate for the presence or absence of significant amyloid plaques (i.e., moderate to frequent levels of neuritic plaques) in the brain. This information is reported back to the referring physician, who then determines the next steps in the evaluation and management of the patient.
Indications and Usage
Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.
Limitations of Use:
A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or monitoring responses to therapies.(1)
Amyvid for intravenous use is supplied in 10 mL, 30 mL, or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F 18.
Important Safety Information
Warnings and Precautions
Risk for Image Misinterpretation and Other Errors
Errors may occur in the Amyvid estimation of brain neuritic plaque density during image interpretation.
Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors. Other errors may be due to extensive brain atrophy that limits the ability to distinguish gray and white matter on the Amyvid scan as well as motion artifacts that distort the image.
Amyvid scan results are indicative of the brain neuritic amyloid plaque content only at the time of image acquisition and a negative scan result does not preclude the development of brain amyloid in the future.
Radiation Risk
Amyvid, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure.
Most Common Adverse Reactions
The most common adverse reactions reported in clinical trials were headache (1.8 percent), musculoskeletal pain (0.8 percent), fatigue (0.6 percent), nausea (0.6 percent), anxiety (0.4 percent), back pain (0.4 percent), blood pressure increased (0.4 percent), claustrophobia (0.4 percent), feeling cold (0.4 percent), insomnia (0.4 percent), neck pain (0.4 percent).
Drug Interactions
Pharmacodynamic drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Amyvid image results.
For Full Prescribing Information, visit http://pi.lilly.com/us/amyvid-uspi.pdf.  
AM HCP ISI 06APR2012
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.  
This press release contains certain forward-looking statements about Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. This release reflects Lilly's current beliefs; however, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that the product will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
P-LLY


(1) Amyvid Prescribing Information. April 6, 2012.
(2) Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging—Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1—13.
(3) Mirra SS, Heyman A, McKeel D, et al; and participating CERAD neuropathologists. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II. standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479—486.
(4) Thies W, Bleiler L; Alzheimer's Association. Alzheimer's Association report: 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8:131—168. 
(5) McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's Disease. Alzheimers Dement. 2011;7:263—269.
(6) Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's Disease. Alzheimers Dement. 2011;7(3):280—292.
©Lilly USA, LLC 2012. All rights reserved. AM77832 5/2012
Amyvid™ is a trademark of Eli Lilly and Company.
SOURCE Eli Lilly and Company


News Provided by Acquire Media

Thursday, April 12, 2012

Eli Lilly Says FDA Approved Alzheimer's Diagnostic Agent Amyvid

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

RTT News

Eli Lilly and Company (LLY: News ) on Friday said the Food and Drug Administration (FDA) has approved Amyvid, a radioactive diagnostic agent for use in patients being evaluated for Alzheimer's Disease and other causes of cognitive decline.

Amyvid or florbetapir F 18 injection is a molecular imaging agent under investigation for the Positron Emission Tomography imaging of beta-amyloid plaque in the brains of Alzheimer's disease patients.

A negative Amyvid scan indicates sparse-to-no amyloid plaques are present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease.

A positive scan indicates moderate to frequent amyloid plaques are present. This amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.

Amyvid was a lead candidate of Avid Radiopharmaceuticals, which became a wholly owned subsidiary of Lilly through its acquisition by the Indianapolis, Indiana-based health care giant in December 2010.

Tuesday, February 14, 2012

Cracks in the Plaques: Mysteries of Alzheimer's Slowly Yielding to New Research

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

Scientific American


Science is bringing some understanding of the heritability, prevalence and inner workings of one of the most devastating diseases
By Daisy Yuhas

This has been a big week in Alzheimer's news as scientists put together a clearer picture than ever before of how the disease affects the brain. Three recently published studies have detected the disease with new technologies, hinted at its prevalence, and described at last how it makes its lethal progress through the brain.

The existence of two forms of Alzheimer's—early- and late-onset—has long baffled scientists. Of the estimated five million Americans who suffer from Alzheimer's, only a few thousand are diagnosed with an early-onset form of the affliction, which affects people before the age of 65. This rare early-onset form is thought to be hereditary and scientists have associated multiple genetic mutations contributing to its occurrence. Late-onset Alzheimer's, although more common, has been the bigger mystery. One variant of the APOE gene-—sometimes known as the Alzheimer's gene—is linked to the late-onset disease. But the APOE gene, unlike dominant early-onset genes, does not determine whether a person will ultimately have dementia.

Now there's evidence that late-onset Alzheimer's has a genetic basis similar to that of early-onset Alzheimer's. By sequencing select genes associated with the latter, along with frontotemporal dementia, researchers at Washington University in Saint Louis and other institutions found that patients with late-onset Alzheimer's carry some of the same genetic mutations as those with the early-onset form. The evidence, published on Wednesday in PLoS ONE, bolsters the argument that the forms of Alzheimer's that appear at different life stages should be classified as the same disease. As to why the disease appears earlier in some cases, the scientists speculated that those patients diagnosed relatively early in life carry more genetic risk factors for the disease.

This study's use of rapid genetic sequencing, the authors noted, may provide a model for more precise identification of dementias. Within the study, the researchers identified patients who may have been misdiagnosed as having Alzheimer's; the genes of these patients suggested that they had another type of dementia. Given the heritable component, patients with a family history could be screened to detect and diagnose Alzheimer's early.

Other genetic research unveiled in the past week or so has shed light on the biological processes that underlie how Alzheimer's affects the brain. Certain mutations may lead to an increased production of a protein called amyloid beta in the region of the brain that creates memory. This excess amyloid beta, naturally secreted by brain cells, then becomes a complex called an oligomer. These oligomers may interrupt the signals transmitted between neurons. As in other neurodegenerative diseases like Parkinson's or Huntington's, the spread of oligomers appears to be driving the disease process.

Oligomer-linked diseases are relatively common, in part because oligomers can also play an essential biological role in the brain. A recent investigation using fruit flies reveals that the presence of a specific oligomer is actually required for the flies to form long-term memories.

In an early stage of Alzheimer's, the naturally secreted amyloid beta protein builds up as oligomers in the brain, which then go on to form larger aggregates called plaques. Later in the disease, another aberrant form of a protein called tau starts to build up, in the entorhinal cortex. Normally, tau helps provide structure crucial to neuron functioning. The buildup of tau, however, causes the protein to tangle and eventually kill brain cells. What was unknown until recently, however, was how the tau protein spreads through different brain regions.

Tuesday, July 5, 2011

Natural Alzheimer's weapon suggests better treatment

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Here are more interesting dementia brain boosting activities




EurekAlert

AUGUSTA, Ga. – Scientists have shown a molecular chaperone is working like a waste management company to collect and detoxify high levels of toxic amyloid beta peptide found in Alzheimer's disease.

It was known that the molecular chaperone, HspB1, was present in the hallmark plaque of Alzheimer's patients but its role remained a mystery.

"What we have found is HspB1 is a protective mechanism that tries to get rid of the toxic oligomers or aggregates of amyloid beta that occur in Alzheimer's," said Dr. Anil G. Cashikar, Biochemist at Georgia Health Sciences University's Center for Molecular Chaperones and Radiobiology. He is corresponding author of the study published in Molecular and Cellular Biology.

Amyloid beta peptide, or Abeta, is believed to start the cascade of events that leads to brain cell damage and death in Alzheimer's: as levels increase, the peptide starts clumping in the brain. In fact, high levels in the spinal fluid are a diagnostic marker for the disease. Molecular chaperones are known for their propensity to respond to disease-producing misfolded proteins, which is how the body views excessive Abeta.

While resulting plaques occupy prime real estate in the brain, it's still better than toxic Abeta killing neurons, Cashikar said. "We think maybe the system gets overwhelmed."

Acknowledging much work remains, the scientist is excited about identifying the protective mechanism and exploring its treatment potential.

Earlier this year, a paper Cashikar published in PLoS One showed deleting genes with a similar function from a mouse model of Alzheimer's worsened disease symptoms. The new study also showed neurons from HspB1-deficient mice were more sensitive to the toxic ravages of Abeta.

"HspB1 is present because its function is to protect cells. The implication is if we can elevate the levels of this molecular chaperone, we may be able to handle the situation a little better," Cashikar said.

He wants to exploit this natural system by developing a smaller version of the molecular chaperone that could be put into the bloodstream to leach excess Abeta from the brain. The brain has a natural protective mechanism that likely would prevent its direct application. However, the natural affinity of amyloid beta and HspB1 indicates a more distant approach could be effective. "We want to come up with smaller versions of HspB1 that can be put into the bloodstream so you can sop up the material from the brain into the blood where it can be cleared more efficiently." He also wants to explore a way to increase brain cells' natural production of protective HspB1.

Neurons actually also make the Abeta believed to attack them in Alzheimer's. The peptide's normal function in the brain is not clear, but early evidence suggests it could be involved in synaptic pruning, which is essential for memory formation. Synapses connect neurons and some existing connections must be cut for new connections and memories to be made. Why neurons start making too much Abeta and how its overproduction can be controlled are million-dollar questions, Cashikar said.

A related ongoing debate is whether the amyloid plaques and neurofibrillarly tangles, insoluble globs of protein also found in Alzheimer's, are a cause or result of the disease. Cashikar's work as well as new studies on the neurofibrillarly tangles, suggest both are protective mechanisms. Also, there is evidence of both in the brains of some healthy, elderly individuals.

GHSU Graduate Student Juhi Ojha is first author on the paper.

Tuesday, November 2, 2010

Is There Another Cause of Alzheimer's Disease?

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Here are more interesting dementia brain boosting activities





Get your subscription to Activity Director Today's e magazine" />

Digital Journal

Scientists doing research at the Jewish General Hospital in Montreal have uncovered one of the root causes of Alzheimer's disease.
This information has raised the hopes of having a drug to slow down or cure or the onset of Alzheimer's disease, a devastating neurodegenerative disorder; as reported in the Montreal Gazette
A neuroscientist named Andrea LeBlanc and other scientists working with her have found that an enzyme in the brain that normally plays a role in inflammation will in certain individuals start Alzheimer's disease process. The enzyme is called Caspase-6. It causes an over-production of amyloid beta plaques that clog up the brains of Alzheimer disease victims thus impairing their memories and cognitive abilities.
LeBlanc thinks that an "estrogen-type" drug might be able to stop Caspase-6. This would effectively treat Alzheimer's disease. Right now, the research is in the early stage, It will take at least 10 years to come up with a potential drug.
"If we could slow the progression of the disease for a few years, we would win a big part of the battle," Leblanc said. "What we want to do is keep people cognitively intact for as long as possible."
Until this time, neuroscientists have focused on the "amyloid theory" as the root cause of Alzheimer's disease. However, Leblanc developed another theory: what if the amyloid plaques were not


Read more of: Is There Another Cause of Alzheimer's Disease?

Monday, November 2, 2009

Health Matters: New Discoveries In The Fight Against Alzheimer's Disease

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting activities

WCTV

Triston Sanders-Medical Anchor

Scientists make a big step in the battle against Alzheimer's Disease.
Doctors with the Mayo Clinic in Jacksonville, Florida managed to remove amyloid plaques from the brains of mice.

Those plaques are a hallmark of the disease.
Researchers found the plaques clear when they injected a protein called "IL6" to the mice's immune system.

The finding's a surprise, because researchers thought the protein would have actually made the plaques worse.

The hope now is to use these findings to develop a new treatment for people with the degenerative disease.

The research appears in the "Faseb Journal," which The Federation Of American Societies For Experimental Biology publishes.

Saturday, October 3, 2009

Can You Catch Alzheimer's?

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting activities

It's a memory-destroying disease that has baffled scientists for decades, but one researcher has a controversial theory: that we can catch it with a kiss.
By Tom McGrath, Men's Health

Rich P. is only in his 20s, but these days he finds himself obsessing over something most guys his age never think twice about: Am I doomed to lose my mind?

In some ways, Rich's anxiety is understandable. "My girlfriend is a social worker who works with the aged, specifically people with Alzheimer's," he says. "So I've seen close up what the disease does to you." Indeed, Alzheimer's disease is characterized by memory loss and confusion, and typically ends with complete disconnection from the world. People in its advanced stages can't care for themselves, recognize loved ones, or remember the lives they lived. (Worried about losing your memory and health as you age? Discover the age erasers for men that can strip away 10 years and leave you looking and feeling younger, longer!)

There's also another, even more personal connection for Rich: His girlfriend's father recently passed away from Alzheimer's. He was one of more than 70,000 Americans who die from the disease every year.

Still, what should worry Rich most isn't what he's witnessed in other people, but what he sees in the mirror. Because there, literally right under his nose, is evidence that the monster that could be responsible for Alzheimer's is already skulking about inside his body, preparing itself, at some point, decades down the road-to attack and destroy his brain.

So here's the question: Is it in you, too?

For years, physicians and Alzheimer's experts have said that the earliest symptoms of the disease typically don't appear until you're in your 60s, 70s, or beyond. But now there's reason to believe that the first warning signs may actually crop up much earlier than that, and in a seemingly much more benign way: as cold sores, those embarrassing blisters that can erupt on the lips of people who are sick or run-down.

The sores are triggered by the herpes virus—most often, herpes simplex virus type 1 (not to be confused with HSV-2, which predominately causes genital herpes). In recent years, a growing body of research, much of it championed by a British scientist, has begun to suggest a startling fact: The same virus known for sabotaging people's social lives could be responsible for the majority of Alzheimer's cases.

"There's clearly a very strong connection," says the researcher, Ruth Itzhaki, Ph.D., speaking one afternoon in her office at the University of Manchester, in northwestern England. A neurobiologist, Itzhaki has spent the better part of two decades studying the link between herpes and Alzheimer's. "I estimate that about 60 percent of Alzheimer's cases could be caused by the virus."

As viruses go, herpes is a particularly devilish bugger. The ancient Greeks were among the first to record the sores it causes (the virus' name is derived from a Greek word meaning "to creep"), and today the microbe is ubiquitous. As many as 85 percent of us have been infected by it, though experts say as few as 15 percent show symptoms. Worse, once you have it, you have it forever: After the initial infection, the virus lies dormant in your peripheral nervous system, occasionally flaring up during periods of stress, illness, or fatigue. You can follow these three steps to prevent a herpes outbreak, but it never completely disappears.

And it's that fact—herpes as the viral equivalent of The Thing That Wouldn't Leave—that lies at the heart of the herpes-Alzheimer's relationship. Research suggests that as we age, HSV-1 actually spreads to our brains, where in certain people, Itzhaki theorizes, it can cause the buildup of deposits—known as amyloid plaques and neurofibrillary tangles—that attack and destroy the cells responsible for memory, language, and physical functions. In short, those people develop Alzheimer's.

It's a provocative theory, one that would sound preposterous if it weren't for the steadily accumulating evidence. Last January, for instance, Itzhaki and her colleague, Matthew Wozniak, Ph.D., published a study in the Journal of Pathology in which they searched for the presence of the herpes virus in people's brains. They found that it resided in 90 percent of the amyloid plaques

Read more about Can You Catch Alzheimer's?
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info